InMed Asking to Open Phase 2 Trial of INM-755, Cannabinol Cream for EB

InMed Asking to Open Phase 2 Trial of INM-755, Cannabinol Cream for EB

293327

InMed Asking to Open Phase 2 Trial of INM-755, Cannabinol Cream for EB

InMed Pharmaceuticals has submitted applications to regulatory authorities in Austria, Israel, and Serbia, seeking clearance to begin clinical testing of its investigational cannabinol cream INM-755 in people with epidermolysis bullosa (EB). Similar applications to authorities in France, Germany, Greece, and Italy are expected in the coming weeks. Responses to these applications are expected this summer, but exact timing varies country-by-country. “It is very exciting to be taking this important next step to test the efficacy…

You must be logged in to read/download the full post.